Advertisement

Advances in Therapy

, Volume 35, Issue 4, pp 482–493 | Cite as

Current Treatment Patterns Among Postmenopausal Women with HR+/HER2− Metastatic Breast Cancer in US Community Oncology Practices: An Observational Study

  • Deborah Goldschmidt
  • Anand A. Dalal
  • Hela Romdhani
  • Sneha Kelkar
  • Annie Guerin
  • Genevieve Gauthier
  • Eric Q. Wu
  • Polly Niravath
  • Tania Small
Original Research

Abstract

Introduction

Recent approval of novel agents has changed the treatment landscape for post menopausal women with hormone receptor-positive (HR+) and human epidermal growth factor receptor-2 negative (HER2−) metastatic breast cancer (mBC). The objective of this study was to describe contemporary treatment patterns among postmenopausal women with HR+/HER2− mBC in the real-world setting.

Methods

Data were collected from 64 community oncologists in the US between February and June 2017 using an online medical records extraction tool. Physicians reviewed medical records and provided information on patient demographics and disease characteristics, and treatment regimens. Treatment patterns were described overall and separately by line of therapy and type of treatment received. Discontinuation rates were estimated using Kaplan–Meier analyses to account for censoring.

Results

Data were collected on 401 patients. Mean age at the time of mBC diagnosis was 67 years. In the first-line setting, 52.4% of patients received a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor-based regimen, most commonly with an aromatase inhibitor (AI) (39.2%) or fulvestrant (10.0%); 30.2% received endocrine therapy, most commonly an AI (21.4%) or fulvestrant (5.2%) in monotherapy, while 12.7% received a chemotherapy-based regimen. In the second-line setting, 42.9% of patients received a CDK4/6 inhibitor-based regimen, 18.4% received endocrine therapy, and 22.4% received a chemotherapy-based regimen. The 18-month discontinuation rate was 34.5% for patients receiving a CDK4/6 inhibitor-based regimen and 45.8% for patients receiving endocrine monotherapy.

Conclusion

CDK4/6 inhibitor-based regimens were the most commonly prescribed treatment in both first- and second-line settings. A wide variety of treatment sequences were observed which suggests an absence of a standard of care for postmenopausal women with HR+/HER2− mBC in real-world practice.

Keywords

CDK4/6 inhibitor Chemotherapy Endocrine therapy Hormone-positive Metastatic breast cancer Oncology Postmenopausal Real-world 

Notes

Acknowledgements

We thank the participants of the study.

Funding

Funding for this research, including the journal’s article processing charges, was provided by Novartis Pharmaceuticals Corporation.

Author contributions

The study sponsor was involved in all stages of the study research and manuscript preparation. All authors participated in the design and analytical approach of the study and contributed to the manuscript development. Results were summarized and interpreted in collaboration with all authors. Manuscript was prepared by the authors with the assistance from a professional medical writer ultimately paid by the sponsor. All authors had full access to all the data in this study and take complete responsibility for the integrity of the data and accuracy of the data analysis

Medical Writing Assistance

Medical writing assistance was provided by Sara Kaffashian, an employee of Analysis Group, Inc. Analysis Group received consulting fees from Novartis for the conduct of this study.

Authorship

All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Disclosures

Anand A. Dalal is a current employee of Novartis Pharmaceuticals Corporation and may own stock/stock options. Tania Small is a former employee of Novartis Pharmaceuticals Corporation and may own stock/stock options. Deborah Goldschmidt is an employee of Analysis Group Inc., which has received consultancy fees from Novartis Pharmaceuticals Corporation. Hela Romdhani is an employee of Analysis Group Inc., which has received consultancy fees from Novartis Pharmaceuticals Corporation. Sneha Kelkar is an employee of Analysis Group Inc., which has received consultancy fees from Novartis Pharmaceuticals Corporation. Annie Guerin is an employee of Analysis Group Inc., which has received consultancy fees from Novartis Pharmaceuticals Corporation. Genevieve Gauthier is an employee of Analysis Group Inc., which has received consultancy fees from Novartis Pharmaceuticals Corporation. Eric Q. Wu is an employee of Analysis Group Inc., which has received consultancy fees from Novartis Pharmaceuticals Corporation. Polly Niravath received honoraria from Novartis as a consultant.

Compliance with Ethics Guidelines

This study is based on retrospective data and does not include any interaction with human participants or animals performed by any of the authors.

Data Availability

The datasets analyzed during the current study are available from the corresponding author upon reasonable request. Please note that institutional review board confirmation will be needed before the data can be shared with additional parties.

References

  1. 1.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30.CrossRefPubMedGoogle Scholar
  2. 2.
    Weide R, Feiten S, Friesenhahn V, Heymanns J, Kleboth K, Thomalla J, et al. Metastatic breast cancer: prolongation of survival in routine care is restricted to hormone-receptor- and Her2-positive tumors. SpringerPlus. 2014;3:535.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
  4. 4.
    National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology (NCCN guidelines). Breast cancer. Version 1.2017: Fort Washington, PA. https://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
  5. 5.
    Shah AN, Cristofanilli M. The Growing role of CDK4/6 inhibitors in treating hormone receptor-positive advanced breast cancer. Curr Treat Options Oncol. 2017;18(1):6.CrossRefPubMedGoogle Scholar
  6. 6.
    Turner NC, Ro J, Andre F, Loi S, Verma S, Iwata H, et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med. 2015;373(3):209–19.CrossRefPubMedGoogle Scholar
  7. 7.
    Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16(1):25–35.CrossRefPubMedGoogle Scholar
  8. 8.
    Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, Masuda N, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17(4):425–39.CrossRefPubMedGoogle Scholar
  9. 9.
    U.S. Food and Drug Administration. Ribociclib (Kisqali) 2017. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm546438.html.
  10. 10.
    US Food and Drug Administration. FDA approves abemaciclib for HR-positive, HER2-negative breast cancer 2017. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm578081.htm.
  11. 11.
    Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375(20):1925–36.CrossRefPubMedGoogle Scholar
  12. 12.
    Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017;35(32):3638–46.CrossRefPubMedGoogle Scholar
  13. 13.
    Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, et al. Ribociclib as first-line therapy for hr-positive, advanced breast cancer. N Engl J Med. 2016;375(18):1738–48.CrossRefPubMedGoogle Scholar
  14. 14.
    Burton T, Byfield SD, Smith GL, Zanotti G, Bell TJ, Perkins JJ, et al. Clinical and economic outcomes by first-line treatment among women with HR+/HER2− metastatic breast cancer in a large US health plan database. Curr Med Res Opin. 2016;32(8):1417–23.CrossRefPubMedGoogle Scholar
  15. 15.
    Swallow E, Zhang J, Thomason D, Tan RD, Kageleiry A, Signorovitch J. Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2−) breast cancer patients in the United States: 2002-2012. Curr Med Res Opin. 2014;30(8):1537–45.CrossRefPubMedGoogle Scholar
  16. 16.
    Andre F, Neven P, Marinsek N, Zhang J, Baladi JF, Degun R, et al. Disease management patterns for postmenopausal women in Europe with hormone-receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer. Curr Med Res Opin. 2014;30(6):1007–16.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Healthcare Ltd., part of Springer Nature 2018

Authors and Affiliations

  • Deborah Goldschmidt
    • 1
  • Anand A. Dalal
    • 2
  • Hela Romdhani
    • 3
  • Sneha Kelkar
    • 1
  • Annie Guerin
    • 3
  • Genevieve Gauthier
    • 3
  • Eric Q. Wu
    • 4
  • Polly Niravath
    • 5
  • Tania Small
    • 2
  1. 1.Analysis Group, Inc.New YorkUSA
  2. 2.Novartis Pharmaceuticals CorporationEast HanoverUSA
  3. 3.Analysis Group, Inc.MontrealCanada
  4. 4.Analysis Group, Inc.BostonUSA
  5. 5.Houston Methodist HospitalHoustonUSA

Personalised recommendations